JAZZ PHARMACEUTICAL (J7Z.SG)
JAZZ PHARMACEUTICAL (J7Z.SG) operates in Diversified Metals & Mining.
JAZZ PHARMACEUTICAL (J7Z.SG) (J7Z) - Total Assets
Latest total assets as of September 2024: €12.26 Billion EUR
Based on the latest financial reports, JAZZ PHARMACEUTICAL (J7Z.SG) (J7Z) holds total assets worth €12.26 Billion EUR as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
JAZZ PHARMACEUTICAL (J7Z.SG) - Total Assets Trend (2016–2023)
This chart illustrates how JAZZ PHARMACEUTICAL (J7Z.SG)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
JAZZ PHARMACEUTICAL (J7Z.SG) - Asset Composition Analysis
Current Asset Composition (December 2023)
JAZZ PHARMACEUTICAL (J7Z.SG)'s total assets of €12.26 Billion consist of 30.2% current assets and 69.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.2% |
| Accounts Receivable | €705.79 Million | 6.2% |
| Inventory | €597.04 Million | 5.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €5.42 Billion | 47.6% |
| Goodwill | €1.75 Billion | 15.4% |
Asset Composition Trend (2016–2023)
This chart illustrates how JAZZ PHARMACEUTICAL (J7Z.SG)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: JAZZ PHARMACEUTICAL (J7Z.SG)'s current assets represent 30.2% of total assets in 2023, an increase from 15.6% in 2016.
- Cash Position: Cash and equivalents constituted 13.2% of total assets in 2023, up from 7.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 62.0% of total assets, a decrease from 80.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 47.6% of total assets.
JAZZ PHARMACEUTICAL (J7Z.SG) Competitors by Total Assets
Key competitors of JAZZ PHARMACEUTICAL (J7Z.SG) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
JAZZ PHARMACEUTICAL (J7Z.SG) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - JAZZ PHARMACEUTICAL (J7Z.SG) generates 0.34x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, JAZZ PHARMACEUTICAL (J7Z.SG) generates $ 3.64 in net profit.
JAZZ PHARMACEUTICAL (J7Z.SG) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.26 | 2.06 | 4.47 |
| Quick Ratio | 3.74 | 1.67 | 4.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.36 Billion | € 1.67 Billion | € 1.27 Billion |
JAZZ PHARMACEUTICAL (J7Z.SG) - Advanced Valuation Insights
This section examines the relationship between JAZZ PHARMACEUTICAL (J7Z.SG)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | €11.39 Billion |
| Market Capitalization | $1.52 Million USD |
Valuation Analysis
Below Book Valuation: The market values JAZZ PHARMACEUTICAL (J7Z.SG)'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: JAZZ PHARMACEUTICAL (J7Z.SG)'s assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for JAZZ PHARMACEUTICAL (J7Z.SG) (2016–2023)
The table below shows the annual total assets of JAZZ PHARMACEUTICAL (J7Z.SG) from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €11.39 Billion | +5.15% |
| 2022-12-31 | €10.84 Billion | -11.90% |
| 2021-12-31 | €12.30 Billion | +88.17% |
| 2020-12-31 | €6.54 Billion | +18.00% |
| 2019-12-31 | €5.54 Billion | +6.45% |
| 2018-12-31 | €5.20 Billion | +1.56% |
| 2017-12-31 | €5.12 Billion | +6.74% |
| 2016-12-31 | €4.80 Billion | -- |